Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation

Show simple item record

dc.contributor.author Leino, Sakari
dc.contributor.author Kohtala, Samuel
dc.contributor.author Rantamäki, Tomi
dc.contributor.author Koski, Sini K.
dc.contributor.author Rannanpää, Saara
dc.contributor.author Salminen, Outi
dc.date.accessioned 2018-12-17T10:49:01Z
dc.date.available 2018-12-17T10:49:01Z
dc.date.issued 2018-11-29
dc.identifier.citation Leino , S , Kohtala , S , Rantamäki , T , Koski , S K , Rannanpää , S & Salminen , O 2018 , ' Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation ' , BMC Neuroscience , vol. 19 , no. 1 , 77 . https://doi.org/10.1186/s12868-018-0478-0
dc.identifier.other PURE: 119727776
dc.identifier.other PURE UUID: 39288064-1c14-47e4-81dc-b216608d3d7f
dc.identifier.other RIS: urn:805D7344DF5A6E29AD9324ADD47D49ED
dc.identifier.other RIS: Leino2018
dc.identifier.other Scopus: 85057485229
dc.identifier.other WOS: 000451702800002
dc.identifier.other ORCID: /0000-0002-0052-1434/work/51804195
dc.identifier.other ORCID: /0000-0003-0427-858X/work/51804244
dc.identifier.other ORCID: /0000-0002-9010-7252/work/51804779
dc.identifier.other ORCID: /0000-0001-9249-085X/work/51806484
dc.identifier.other ORCID: /0000-0002-3419-606X/work/51806980
dc.identifier.uri http://hdl.handle.net/10138/276973
dc.description.abstract BackgroundThe treatment of Parkinson's disease is often complicated by levodopa-induced dyskinesia (LID). Nicotinic acetylcholine receptor agonists can alleviate LID in animal models but may be less effective in conditions of severe dopaminergic denervation. While the mechanisms of LID remain incompletely understood, elevated corticostriatal levels of the brain-derived neurotrophic factor (BDNF) have been suggested to play a role. Here, female mice with near-total unilateral 6-hydroxydopamine-induced nigrostriatal lesions were chronically treated with levodopa, and the effects of the 7 nicotinic receptor partial agonist AZD0328 and nicotine on LID were assessed. At the end of the experiment, BDNF protein levels in the prefrontal cortex and striatum were measured.ResultsFive-day treatments with three escalating doses of AZD0328 and a 10-week treatment with nicotine failed to alleviate LID. BDNF levels in the lesioned striatum correlated positively with LID severity, but no evidence was found for a levodopa-induced elevation of corticostriatal BDNF in the lesioned hemisphere. The nicotine treatment decreased BDNF levels in the prefrontal cortex but had no effect on striatal BDNF.ConclusionsThe findings suggest that treatment of LID with nicotinic agonists may lose its effectiveness as the disease progresses, represent further evidence for a role for BDNF in LID, and expand previous knowledge on the effects of long-term nicotine treatment on BDNF. en
dc.format.extent 10
dc.language.iso eng
dc.relation.ispartof BMC Neuroscience
dc.rights cc_by_nc
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject AQW051
dc.subject Alpha7 nicotinic receptors
dc.subject BDNF
dc.subject DOPA-INDUCED DYSKINESIAS
dc.subject EXPRESSION
dc.subject IMPROVEMENT
dc.subject INCREASES
dc.subject Levodopa-induced dyskinesia
dc.subject MODEL
dc.subject MOTOR
dc.subject Nicotine
dc.subject PARKINSONS-DISEASE
dc.subject Parkinson's disease
dc.subject RATS
dc.subject SYNAPTIC PLASTICITY
dc.subject 3112 Neurosciences
dc.title Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation en
dc.type Article
dc.contributor.organization Regenerative pharmacology group
dc.contributor.organization Division of Pharmacology and Pharmacotherapy
dc.contributor.organization Clin­ical Phar­macy Group
dc.contributor.organization Faculty of Pharmacy
dc.contributor.organization Laboratory of Neurotherapeutics
dc.contributor.organization Biosciences
dc.contributor.organization Drug Research Program
dc.contributor.organization Physiology and Neuroscience (-2020)
dc.contributor.organization Outi Salminen / Principal Investigator
dc.contributor.organization Divisions of Faculty of Pharmacy
dc.contributor.organization DAPHNE - Developing Assessment Practices in Higher Education
dc.contributor.organization Teachers' Academy
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1186/s12868-018-0478-0
dc.relation.issn 1471-2202
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
s12868_018_0478_0.pdf 1.119Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record